Zacks Small Cap Weighs in on TNXP Q1 Earnings

Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP - Free Report) - Equities research analysts at Zacks Small Cap issued their Q1 2025 earnings per share (EPS) estimates for shares of Tonix Pharmaceuticals in a report released on Thursday, April 3rd. Zacks Small Cap analyst D. Bautz expects that the company will post earnings of ($3.37) per share for the quarter. The consensus estimate for Tonix Pharmaceuticals' current full-year earnings is ($1,762.50) per share. Zacks Small Cap also issued estimates for Tonix Pharmaceuticals' Q2 2025 earnings at ($12.49) EPS, Q3 2025 earnings at ($4.49) EPS, Q4 2025 earnings at ($5.03) EPS, FY2025 earnings at ($16.43) EPS and FY2026 earnings at ($7.80) EPS.

Tonix Pharmaceuticals (NASDAQ:TNXP - Get Free Report) last posted its earnings results on Tuesday, March 18th. The company reported ($9.77) EPS for the quarter, missing analysts' consensus estimates of ($6.23) by ($3.54). Tonix Pharmaceuticals had a negative return on equity of 163.95% and a negative net margin of 1,197.86%. The firm had revenue of $2.58 million for the quarter, compared to analysts' expectations of $3.20 million.

Several other analysts also recently issued reports on TNXP. Noble Financial reaffirmed an "outperform" rating and issued a $70.00 price target on shares of Tonix Pharmaceuticals in a report on Thursday, March 20th. StockNews.com started coverage on Tonix Pharmaceuticals in a research note on Monday, February 10th. They issued a "sell" rating on the stock.

Remove Ads

Tonix Pharmaceuticals Price Performance

Shares of Tonix Pharmaceuticals stock traded down $0.42 on Monday, hitting $16.88. The company's stock had a trading volume of 478,564 shares, compared to its average volume of 752,090. The company has a quick ratio of 2.81, a current ratio of 3.33 and a debt-to-equity ratio of 0.07. The firm has a fifty day moving average price of $15.14 and a 200-day moving average price of $20.39. Tonix Pharmaceuticals has a 52-week low of $6.76 and a 52-week high of $672.00. The company has a market capitalization of $108.62 million, a P/E ratio of 0.00 and a beta of 1.50.

Institutional Investors Weigh In On Tonix Pharmaceuticals

Several hedge funds have recently modified their holdings of TNXP. Commonwealth Equity Services LLC purchased a new position in shares of Tonix Pharmaceuticals during the fourth quarter valued at approximately $40,000. Two Sigma Investments LP purchased a new position in shares of Tonix Pharmaceuticals during the 4th quarter worth $66,000. PFG Investments LLC acquired a new stake in shares of Tonix Pharmaceuticals during the fourth quarter worth $72,000. Northern Trust Corp purchased a new stake in shares of Tonix Pharmaceuticals in the fourth quarter valued at $162,000. Finally, Rhumbline Advisers acquired a new position in Tonix Pharmaceuticals in the first quarter valued at $244,000. 82.26% of the stock is owned by institutional investors and hedge funds.

Tonix Pharmaceuticals Company Profile

Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company, focuses on developing, discovering, commercializing, and licensing therapeutics to treat and prevent human disease and alleviate suffering. It markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults.